KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB: PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, will hold a special meeting of stockholders to vote on the change of the company's name to Provectus Biopharmaceuticals, Inc. and reincorporation of the Company in the State of Delaware from the State of Nevada. The special meeting of stockholders will be held on December 16, 2013 at 4:00 pm EST at the law offices of Baker, Donelson, Bearman, Caldwell & Berkowitz, PC, which is located at 265 Brookview Centre Way, Suite 600, Knoxville, Tennessee 37819.
Dr. Craig Dees, PhD, CEO of Provectus, said, “We believe that these two proposals demonstrate our commitment to protecting our shareholders’ interests and communicating with the markets about our business and our plans for the future.
“Changing our name to ‘Provectus Biopharmaceuticals, Inc.’ will better communicate to the public the current and future nature of our business operations and enable us to better implement our business plan. The new name, if approved, would not affect our business, operations, reporting requirements or stock price but will require a new CUSIP.
“Reincorporation in Delaware will give us more flexibility, clarity and predictability with respect to our corporate governance. The corporate laws in Delaware are more comprehensive, widely-used and extensively interpreted than those of other states, including Nevada. In addition, Delaware provides a recognized body of corporate law that is consistently interpreted by Delaware courts, which we believe will facilitate corporate governance by our officers and directors.”
About Provectus Pharmaceuticals, Inc.
Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.
